Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Lyell Immunopharma, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.66
7.76
10.7
84.7
0.13
0.06
0.04
Research and development
63.6
182
139
159
183
172
159
General and administrative
39.2
46.9
89.1
117
67
52
45.1
Operating expenses
103
220
225
272
247
359
269
Operating income
-102
-212
-215
-187
-247
-359
-269
Other non-operating income
-27.3
7.47
-35.4
3.94
12.4
15.8
-5.04
Income tax
0
Net income
-129
-204
-250
-183
-235
-343
-274
EBITDA
-101
-208
-201
-169
-227
-339
-258
EPS, basic
-483.38
-315.49
-37.00
-14.88
-18.70
-26.23
-16.06
EPS, diluted
-483.39
-315.49
-37.00
-14.88
-18.70
-26.23
-16.06
Shares, basic (weighted)
0
0.66
6.76
12.3
12.5
13.1
17.1
Shares, diluted (weighted)
0
0.66
6.76
12.3
12.5
13.1
17.1
Balance sheet
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
96.7
140
294
124
146
106
60.2
Short-term investments
472
321
517
401
265
187
Other current assets
4.93
11.5
11.1
8.46
9.07
13.7
Total current assets
618
626
651
555
380
261
Property, plant and equipment
77
120
123
103
48.2
34.8
Lease right-of-use assets
47
46.5
43.2
39.7
24.7
18.9
Long-term investments
80
284
70.1
16.5
13
0
Other non-current assets
2.77
3.48
4.68
4.24
4.62
4.89
Total assets
908
1,127
938
750
491
340
Accounts payable
9.4
3.21
3.92
4.82
5.37
2.89
Deferred revenue
6.1
4.99
0
Total current liabilities
49.3
46.7
37
34.5
53.8
49.4
Lease liabilities
51
66.7
63.2
56.9
51
41.9
Other non-current liabilities
0.53
4.57
4.11
3.66
3.25
0.52
Total liabilities
190
198
104
95.1
108
91.9
Paid-in capital
41.4
1,516
1,608
1,657
1,728
1,868
Retained earnings
-334
-584
-767
-1,002
-1,345
-1,620
Other comprehensive income
0.26
-1.62
-7.6
-0.09
0.29
0.24
Shareholders' equity
-111
-293
930
833
655
383
248
Total equity
-111
-293
930
833
655
383
248
Total liabilities and equity
908
1,127
938
750
491
340
Shares outstanding
0.77
12.1
12.4
254
14.7
21.3
Cash flow statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-129
-204
-250
-183
-235
-343
-274
Depreciation and amortization
1.26
4.29
13.6
18
20.3
19.6
11.5
Stock-based compensation
15.7
33.3
62.2
81.9
47.1
33.1
41.8
Change in payables
1.71
-0.28
0.09
0.67
1.46
-3.23
-2.34
Cash from operations
39.5
-161
-126
-170
-164
-162
-150
Capital expenditures
-16
-51.5
-65.5
-24.3
-2.69
-0.46
-0.78
Purchases of investments
-611
-865
-673
-406
-477
-395
-279
Cash from investing
-422
-274
-122
-11.5
184
122
54.1
Stock issued
0
0.37
9.44
9.58
0
0
50
Share buybacks
-0.19
-11.8
0
0
Cash from financing
351
477
401
10.6
1.74
1.33
50.4
Net change in cash
-31.8
42.4
153
-170
22.1
-38.6
-45.5
Free cash flow
23.4
-212
-192
-194
-166
-163
-151
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $9.85 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-949,981.0%
Operating income / revenue.
EBITDA margin
-914,733.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-920,285.0%
Net income / revenue.
FCF margin
-496,189.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-493,556.0%
Cash from operations / revenue.
Return on equity (ROE)
-106.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-79.9%
Net income / average total assets.
Return on invested capital (ROIC)
-126.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Stock-based pay / revenue
146,770.0%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
2,633.0%
Capital expenditures / revenue.
D&A / revenue
35,248.0%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-41.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-92.5%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-65.9%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-35.2%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-33.2%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-30.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-28.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-17.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
30.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
11.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
91.8%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
5.36x
Current assets / current liabilities.
Quick ratio
5.12x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
5.12x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
FCF per share
-$5.73
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$5.70
Cash from operations / diluted weighted shares.
Book value per share
$9.99
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
8,940x
Market cap / revenue.
P/B
1.03x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.03x
Market cap / tangible book value, when positive.
EV/Sales
1,381x
Enterprise value / revenue.
FCF yield
-55.5%
Free cash flow / market cap.
Earnings yield
-102.9%
Net income / market cap (the inverse of P/E).
What was Lyell Immunopharma, Inc.'s revenue in fiscal 2025?
Lyell Immunopharma, Inc. reported revenue of $36.0K for fiscal 2025, 41% lower than the year before.
Was Lyell Immunopharma, Inc. profitable in fiscal 2025?
No. It reported a net loss of $274.4M.
How much free cash flow did Lyell Immunopharma, Inc. generate in fiscal 2025?
Cash from operations of $150.0M minus capital expenditures of $780.0K left free cash flow of -$150.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.